Biotech company AXIM Biotechnologies has launched clinical trials for medical cannabis chewing gum that they hope will successfully treat conditions such as multiple sclerosis, irritable bowel disease and Crohn’s Disease.
AXIM already has a cannbinoid chewing gum on the market, called CanChew but it does not contain the psychoactive ingredient THC, and it makes no claims that it can treat any condition.
The psychoactive ingredient, THC, is an effective way of treating patients with degenerative diseases, while the medicinal properties of cannabidiol are known to treat neurological conditions such as epilepsy. Chewing the gum is said to preserve cognition and memory, as well as promoting overall gum and dental health, according to George Anastassov, chief executive of AXIM. He added that AXIM hopes to eventually be able to start more cannabis chewing gum trials that will effectively treat a whole range of medical conditions besides multiple sclerosis.
If the gum (MedChew) is approved by the FDA, it could be available in all states, even certain states that have not legalized medical marijuana. Axim maintains that their product is different from other cannabis infused gums because it is time released. This means that the distribution of cannabinoids to the gastrointestinal tract happens gradually over a period of around half an hour, a process, the company claims, is similar to the technology behind nicotine gum.
Cannabis and pain relief for multiple sclerosis
Multiple Sclerosis or MS, is a progressive, degenerative disease that can affect the brain, spinal cord, and even the optic nerves in one’s eyes. It can cause problems with vision, balance, muscle control, and other basic body functions. Although the effects are often different for individuals with the disease, generally pain is a predominant symptom.
While there is no cure for MS, current treatments work to speed recovery from attacks and work to slow progression of the disease. Commonly, patients are subjected to physical therapy, muscle relaxants and other medications to reduce fatigue and depression which are other symptoms of multiple sclerosis. Cannabis is known to help manage these symptoms. Many people report that it has helped them to overcome the pain and inflammation associated with the disease.
The Phase 1 trial of the gum is slated to begin in the second quarter of 2016.